Valley Cottage, NY — 12/19/2017 — Osteoporosis is a bone disorder characterized by low mineral density and bone mass, affecting 70 % of the U.S. population. Osteoporosis is most common in women than in men. These affected population are at high risk of fragility fracture, which most commonly occurs in wrist, upper arm, knee, hip and spine. Prevalence of osteoporosis is high among people aged 60 years and above. Moreover, estrogen plays a vital role in regulating the bone growth process in women. The rate of bone loss in women increases after menopause, leading to the threat of developing osteoporosis. Annually, 8.9 million fractures are reported to occur from osteoporosis across the globe. Anti-osteoporotic therapy is a treatment intended to increase bone mineral density and control the loss of bone tissue. Anti-osteoporosis can decrease the risk of subsequent fractures by 40%. Most of anti-osteoporosis therapy drugs are derived from the bisphosphonate molecule. Various studies have reported that these drugs can indeed increase bone mineral density (BMD) and reduce the risk of vertebral, hip, and other non-vertebral fractures in women with osteoporosis.
Increasing prevalence of osteoporosis in post-menopausal women, increasing incidence of geriatric population, rise in incidence of people suffering from osteoporosis and changing lifestyle impacting bone health are some of the factors driving growth of the global anti-osteoporosis therapy and fracture healing market. In addition, growing investments in R&D for the discovery of innovative drugs and increasing awareness about osteoporosis care are also fueling the growth of the anti-osteoporosis therapy and fracture healing market.
Due to rising prevalence of osteoporosis the global anti-osteoporosis and fracture healing market is expected to have a robust growth in the forecast period (2015-2025). Moreover, increasing prevalence of osteoporosis in post-menopausal women and increase in incidence of geriatric population across the globe are likely to fuel the demand for anti-osteoporosis therapy and fracture healing market in upcoming years.
Major players in this market are Actavis plc, Eli Lilly and Company, Merck and Company Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., F. Hoffmann La Roche Ltd., Novartis International AG., Pfizer, Inc., and GlaxoSmithKline plc.
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
Latest posts by Brad Bennett (see all)
- Loyale Healthcare Announces Expanded Partner Strategy, Promotes Grattan Smith to Lead Effort - February 22, 2018
- Robert J. McKennon and McKennon Law Group PC Receive Top Attorneys Awards - February 22, 2018
- Revived California Plant Celebrates Production of Low-Carbon Biodiesel - February 22, 2018